0001517022-26-000020 Sample Contracts
AKEBIA THERAPEUTICS, INC. STOCK OPTION AGREEMENT FOR OFFICERSStock Option Agreement • February 26th, 2026 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
Akebia Therapeutics, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2023 Stock Incentive Plan, as amended (the “Plan”). The terms and conditions attached hereto are also a part hereof.
EXECUTIVE SEVERANCE AGREEMENTExecutive Severance Agreement • February 26th, 2026 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This EXECUTIVE SEVERANCE AGREEMENT (the “Agreement”) is entered into by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia” or the “Company”), and _________________, a resident of _______________ (the “Executive”), and is effective as of ____________ (the “Effective Date”).
AKEBIA THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT FOR OFFICERSRestricted Stock Unit Agreement • February 26th, 2026 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT #1 TO LICENSE...License Agreement • February 26th, 2026 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • England and Wales
This AMENDMENT #1 TO LICENSE AGREEMENT (this “Amendment #1”), by and between Akebia Therapeutics, Inc., a corporation organized and existing under the laws of the state of Delaware with its principal offices at 245 First Street, Cambridge, MA 02142 (“Akebia”), and MEDICE Arzneimittel Pütter GmbH & Co. KG, a limited partnership organized under the laws of Germany, with corporate domicile at Kuhloweg 37, 58638 Iserlohn, Germany, registered at local court Iserlohn, HRA 1037 (“Licensee”), represented by its general partner Medice Verwaltungs-GmbH, a private liability company with identical corporate domicile, registered at local court Iserlohn, HRB 200, represented by Dr. Richard Ammer, is effective as of November 10, 2025 (the “Amendment Effective Date”). Akebia and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
WALTHAM, MASSACHUSETTS Lease Dated January 26, 2026 (“Execution Date”)Lease • February 26th, 2026 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
THIS INSTRUMENT IS AN INDENTURE OF LEASE (this “Lease”) in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in the building known as 180 CityPoint and having an address at 180 Third Avenue, Waltham, Massachusetts 02451.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • February 26th, 2026 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made effective as of June 3, 2021 (the “Effective Date”) by and between Cyclerion Therapeutics, Inc., a Massachusetts corporation (“Cyclerion”) and Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”) (each of Cyclerion and Akebia being a “Party”, and collectively, the “Parties”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT #1 TO LICENSE...License Agreement • February 26th, 2026 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
This Amendment #1 (the “Amendment”) to the License Agreement (the “License Agreement”) dated June 3, 2021 by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”), and Cyclerion Therapeutics, Inc., a Massachusetts corporation (“Cyclerion”) is effective as of December 13, 2024 (the “Amendment Effective Date”). Akebia and Cyclerion are each referenced individually herein as a “Party” and together as the “Parties”. Any capitalized terms used but not herein defined shall have the meaning set forth for such term in the License Agreement.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ASSET PURCHASE...Asset Purchase Agreement • February 26th, 2026 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
This ASSET PURCHASE AGREEMENT, dated as of November 28, 2025 (this “Agreement”), is made by and between Akebia Therapeutics, Inc., a Delaware corporation (“Buyer”), on the one hand, and Q32 Bio Inc., a Delaware corporation, and Q32 Bio Operations Inc., a Delaware corporation (together, the “Seller”), on the other hand. Buyer and Seller are each referred to as a “Party,” and, together, the “Parties.” Capitalized terms used herein shall have the meanings assigned to such terms in the text of this Agreement or in Section 7.1 (Certain Terms).